Development of the Preclinical Phase of Peptidic Drugs Derived from Cementum Protein and Cementum Attachment for the Treatment of Osteoporosis
Objectives: To determine whether the synthetic peptides CAP-p5 and CEMP1-p1 can correct the osteoporotic state (by increasing bone mineral density and recovery of bone microarchitecture) in an osteoporosis murine model. Methods: Experimental study. 4 groups were created, 5 animals each, after ovarectomy they were treated either with: Group 1. CAP-p5 20 mg/day, or Group 2. CEMP1-p1 80 mg/day, Group 3: Ovarectomized control rats group, Group 5: Non- osteoporotic rats. Experimental animals were IP injected up to 90 days Results: The results indicate that mechanical compression forces of the 5th lumbar vertebra, have similar values in those treated with the peptides and compared with non-osteoporotic animals. Regarding bone mineral density (BMD), the trabecular number and thickness of the lumbar vertebrae and femur increased in the experimental groups. Biological markers (ALP, OCN, RANK1 and OPG) show similar values to the non-osteoporotic animals. Histological analyzes show that in the groups treated with the peptides there is bone neoformation in trabeculae and there is no ectopic bone formation. Conclusions: Peptides from cementum proteins show high therapeutic effectiveness for the treatment osteoporosis in an experimental model. Supported by DGAPA-UNAM IT200717.